Iowa 2025 2025-2026 Regular Session

Iowa Senate Bill SF433 Introduced / Bill

Filed 02/25/2025

                    Senate File 433 - Introduced   SENATE FILE 433   BY WAHLS   A BILL FOR   An Act relating to direct acting antiviral medications, 1   including prior authorization requirements, and the Iowa 2   medical assistance drug utilization review commission. 3   BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 4   TLSB 1440XS (4) 91   lh/ko  

  S.F. 433   Section 1. DIRECT ACTING ANTIVIRAL MEDICATION  MEDICAID 1   PRIOR AUTHORIZATION. Notwithstanding section 249A.20A, 2   subsection 4, the department of health and human services shall 3   not require prior authorization for any direct acting antiviral 4   medications used to treat hepatitis C that are on the preferred 5   drug list. 6   Sec. 2. IOWA MEDICAL ASSISTANCE DRUG UTILIZATION REVIEW 7   COMMISSION  VOSEVI REVIEW. The Iowa medical assistance drug 8   utilization review commission created under section 249A.24 9   shall, by July 1, 2026, review the prescription drug vosevi for 10   placement on the preferred drug formulary pursuant to 42 U.S.C. 11   1396r-8 as a preferred direct acting antiviral for treatment 12   of hepatitis C. 13   EXPLANATION 14   The inclusion of this explanation does not constitute agreement with 15   the explanations substance by the members of the general assembly. 16   This bill relates to direct acting antivirals, including 17   prior authorization requirements, and the Iowa medical 18   assistance drug utilization review commission (commission). 19   The bill prohibits the department of health and human 20   services from requiring prior authorization for direct acting 21   antiviral medications used to treat hepatitis C that are on the 22   preferred drug list for the medical assistance program. 23   The bill requires the commission to review, by July 1, 2026, 24   the prescription drug vosevi for placement on the preferred 25   drug list pursuant to 42 U.S.C. 1396r-8 as a preferred direct 26   acting antiviral for treatment of hepatitis C. 27   -1-   LSB 1440XS (4) 91   lh/ko 1/ 1